A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy and safety of 12 weeks once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (delivered by the Respimat Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy and safety of 12 weeks once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (delivered by the Respimat Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 16 Jun 2016 Last checked against UK Clinical Trials Register record.
    • 30 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 22 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by UK Clinical Trials Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top